Clinical Trial Update: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial update evaluating alpha-1 antitrypsin for the prevention of graft-versus-host disease in patients undergoing hematopoietic cell t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Alpha-1 Antitrypsin (alpha-1 antitrypsin)

Snippet

Sponsor: CSL Behring | Conditions: Acute-graft-versus-host Disease | Phase 2, Phase 3 | Status: COMPLETED